KROSKROS

The net margin of -256.6% — note this figure may be distorted due to a one-time item or data anomaly — indicates the company is significantly unprofitable on a trailing twelve-month basis, which is typical for a pre-revenue clinical-stage biotech. The debt/equity ratio of 0.0x reflects a clean, conservative balance sheet with no long-term debt, reducing financial distress risk from leverage. The current ratio of 15.45x indicates very strong short-term liquidity, suggesting Keros has ample cash to fund near-term operations and clinical trials. However, free cash flow is not available for analysis, making it impossible to assess the company's cash burn rate or operational cash efficiency. Overall, the financial health is conflictual — the balance sheet and liquidity are strong, but the core drug development model is cash-intensive and unprofitable, meaning the company will require ongoing access to capital markets or a partnership to sustain its pipeline.

- EARNINGS QUALITY — The reported net margin of -256.6% — note this figure may be distorted due to a one-time item or data anomaly — is outside the normal range for a pre-revenue biotech and raises questions about the reliability of reported profitability. - REVENUE DECELERATION — Revenue collapsed by -84.5% year-over-year, a severe decline that removes the limited recurring revenue base the company previously reported. - VALUATION DIVERGENCE — The P/E ratio of 2.45x is a misleading proxy for valuation, as it is mechanically depressed by a net income figure that includes non-operating distortions rather than sustainable earnings power. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - 52-WEEK POSITION — The 52-week high/low range is not available, making it impossible to assess whether the current price is near its cycle top or bottom from a technical perspective.